jRCT2031250554招募中不适用
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domainactivating HER2 mutations (Beamion LUNG-3)
未提供0 个研究点目标入组 400 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •1 Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
- •2 Patients must be more than 18 years old or over the legal age of consent in their country
- •3 Histology and tumor sample: Histologically confirmed diagnosis of primary NSCLC etc...
排除标准
- •Diagnosis of NSCLC with mixed histology/positive neuroendocrine markers (synaptophysin/CD56)
- •Presence of any co-occurring actionable mutation for which there is an approved targeted therapy in the adjuvant/neoadjuvant setting (e.g. EGFR or ALK). Patients with non-activating EGFR mutations can be considered eligible
- •Incomplete or aborted surgical resection (R1 or greater) etc...
研究者
相似试验
招募中
1 期
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)Non-small cell lung cancer2024-511246-39-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.162
招募中
3 期
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations compared with standard treatmentNon-small cell lung cancer2025-521284-12-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.21
招募中
不适用
sac-TMT in 1L Maintenance Treatment of Non-HRD Positive Advanced EOCOvarian cancerjRCT203125064745
招募中
3 期
A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patients with PD L1 expression ≥50% on tumor cells : PERSEE TRIAL2024-513697-22-00Centre Hospitalier Regional Et Universitaire De Brest349
招募中
不适用
A Prospective Single-Center Exploratory Study of Letermovir for Cytomegalovirus Prophylaxis in Perioperative Liver TransplantationCytomegalovirus(CMV) infectionjRCT103125078530